Stock Analiz

Cartesian Therapeutics, Inc. RNAC

Biotechnology: Pharmaceutical Preparations · IPO 2016 · data as of November 13, 2026

$6.35Market cap $194M
Open the interactive analysis →

Cartesian Therapeutics, Inc. (RNAC) is a healthcare company listed in the US with a market value of about $194M. In the twelve months to September 30, 2026 it had revenue of $1M and net income of -$127M, a net margin of -12435.2%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -30% a year, a 5-year average ROIC of -161%.

About Cartesian Therapeutics

Cartesian Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2016. Revenue went from $3M in 2014 to $3M in 2025, a decline of about 0.8% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 434% over three years (dilution for shareholders). It spends 2075% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S189.0
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-46.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-92.8%
Revenue growth (5 yrs, per year)-30.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1140.2%
ROIC (5-yr avg.)-161.1%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$1M$3M$39M$26M$111M$85M$17M$7M$903000$207000$8M
Net income-$127M-$130M-$77M-$220M$35M-$26M-$69M-$55M-$65M-$65M-$36M
Free cash flow-$90M-$79M-$33M-$51M-$33M-$61M$34M-$51M-$60M-$53M-$20M
EPS (diluted)$-4.95$-5.02$-4.49$-49.76$3.00$-6.60$-20.40$-36.60$-87.60$-96.00$-116.70
Net margin-12435.2%-4658.6%-199.0%-844.9%31.9%-30.2%-415.0%-829.0%-7235.4%-31556.0%-448.0%
ROIC——-482.9%—10.9%-11.3%—-598.2%—-97.2%-49.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Cartesian Therapeutics pay a dividend?

Not currently.

Is Cartesian Therapeutics a good stock to buy?

We do not give buy or sell advice. Cartesian Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.